Level Biotechnology Inc. (TPEX:3118)

Market Cap	993.06M -9.9%
Revenue (ttm)	709.37M -3.5%
Net Income	76.02M +10.3%
EPS	2.33 +9.9%
Shares Out	32.45M
PE Ratio	13.13
Forward PE	n/a
Dividend	2.20 (7.19%)
Ex-Dividend Date	Jun 10, 2026

Volume	3,355
Open	30.55
Previous Close	30.65
Day's Range	30.55 - 30.60
52-Week Range	30.40 - 34.70
Beta	0.23
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 9, 2026

About Level Biotechnology

Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. The company markets and distributes biomedical precision equipment. It also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the biotech, pharmaceutical, medical device, animal health, and agrichemical industries. The company was founded in 1989 and is headquartered in New Taipei Ci...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1989
• Employees: 128
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 3118

Financial Performance

In 2025, Level Biotechnology's revenue was 736.59 million, an increase of 0.72% compared to the previous year's 731.35 million. Earnings were 79.70 million, an increase of 22.97%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 30, 2026

Data Sources Report a data error